A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced Non-Small Cell Lung Cancer With an FGFR Alteration Who Progressed on Previous Therapy (FIGHT 210)

Grants and Contracts Details

StatusFinished
Effective start/end date5/31/22 → 5/10/24

Funding

  • Incyte Corporation: $29,825.00